MedTrace Logo

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

NCT06200597 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-12-17

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.

Conditions

  • Healthy Volunteers

Interventions

DRUG

LAD603

LAD603 SC injection.

OTHER

Placebo

Matching placebo SC injection.

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2025-05-11
Completion
2025-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200597 on ClinicalTrials.gov